Laboratorios Farmaceuticos Valuation
Laboratorios Farmaceuticos seems to be fairly valued based on Macroaxis valuation methodology. Our model forecasts the value of Laboratorios Farmaceuticos from analyzing the firm fundamentals such as Profit Margin of 0.23 %, return on equity of 0.39, and Current Valuation of 1.93 B as well as examining its technical indicators and probability of bankruptcy.
Laboratorios Farmaceuticos Total Value Analysis
Laboratorios Farmaceuticos ROVI is at this time forecasted to have takeover price of 1.93 B with market capitalization of 2.1 B, debt of 52.52 M, and cash on hands of 126.82 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Laboratorios Farmaceuticos fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.93 B | 2.1 B | 52.52 M | 126.82 M |
Laboratorios Farmaceuticos Investor Information
About 60.0% of the company outstanding shares are owned by corporate insiders. The book value of Laboratorios Farmaceuticos was at this time reported as 8.28. The company last dividend was issued on the 5th of July 2022. Based on the key indicators related to Laboratorios Farmaceuticos' liquidity, profitability, solvency, and operating efficiency, Laboratorios Farmaceuticos ROVI is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Laboratorios Farmaceuticos Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Laboratorios Farmaceuticos has an asset utilization ratio of 88.54 percent. This indicates that the Company is making €0.89 for each dollar of assets. An increasing asset utilization means that Laboratorios Farmaceuticos ROVI is more efficient with each dollar of assets it utilizes for everyday operations.Laboratorios Farmaceuticos Ownership Allocation
Laboratorios Farmaceuticos maintains a total of 51.32 Million outstanding shares. Laboratorios Farmaceuticos ROVI secures majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 60.25 % of Laboratorios Farmaceuticos ROVI outstanding shares that are owned by insiders conveys that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Laboratorios Farmaceuticos Profitability Analysis
The company reported the revenue of 648.68 M. Net Income was 182.63 M with profit before overhead, payroll, taxes, and interest of 379.83 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Laboratorios Farmaceuticos' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Laboratorios Farmaceuticos and how it compares across the competition.
About Laboratorios Farmaceuticos Valuation
The stock valuation mechanism determines Laboratorios Farmaceuticos' current worth on a weekly basis. Our valuation model uses a comparative analysis of Laboratorios Farmaceuticos. We calculate exposure to Laboratorios Farmaceuticos's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Laboratorios Farmaceuticos's related companies.Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. Laboratorios Farmaceticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L. LABORATORIOS FARMACEUTICOS operates under Biotechnology classification in Spain and is traded on Madrid SE C.A.T.S.. It employs 1499 people.
8 Steps to conduct Laboratorios Farmaceuticos' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Laboratorios Farmaceuticos' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Laboratorios Farmaceuticos' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Laboratorios Farmaceuticos' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Laboratorios Farmaceuticos' revenue streams: Identify Laboratorios Farmaceuticos' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Laboratorios Farmaceuticos' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Laboratorios Farmaceuticos' growth potential: Evaluate Laboratorios Farmaceuticos' management, business model, and growth potential.
- Determine Laboratorios Farmaceuticos' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Laboratorios Farmaceuticos' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Laboratorios Stock analysis
When running Laboratorios Farmaceuticos' price analysis, check to measure Laboratorios Farmaceuticos' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Laboratorios Farmaceuticos is operating at the current time. Most of Laboratorios Farmaceuticos' value examination focuses on studying past and present price action to predict the probability of Laboratorios Farmaceuticos' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Laboratorios Farmaceuticos' price. Additionally, you may evaluate how the addition of Laboratorios Farmaceuticos to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| CEOs Directory Screen CEOs from public companies around the world |